RxSight Sees Q2 Revenue Of $32M-$34M; Sees FY2026 Revenue Of $140M-$160M
RxSight, Inc. (NASDAQ: RXST ) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular